Effects of Vericiguat on the Mitochondrial Function and Clinical Outcomes in CRT Nonresponders Patients

Key Points

• This research investigates how vericiguat affects mitochondrial function and clinical outcomes in patients who do not respond to cardiac resynchronization therapy (CRT).
• Evaluated the effects of vericiguat in a small cohort of CRT nonresponders.
• Measured mitochondrial function and levels of inflammatory/oxidative stress.
• Assessed CRT response after one year of treatment.
• Vericiguat increased CRT response in the cohort at one year.
• Improved mitochondrial function observed, likely contributing to the response.
• Reduced levels of inflammatory and oxidative stress were noted.